Drugs / ENS-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06469385 | Sep 2024 → Aug 2025 | atopic eczema | Concerto Biosciences | Terminated | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-28 | Concerto Biosciences | Results Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis concertobio.com ↗
Concerto Biosciences®, a clinical-stage biotech company developing microbial products for therapeutics and consumer markets, today announced positive topline results from its first-in-human Phase 1b clinical trial evaluating ENS-002, a topical three-strain live biotherapeutic product for mild-to-moderate atopic dermatitis (AD). |
| 2024-06-26 | Concerto Biosciences | Regulatory Concerto Biosciences Receives FDA Investigational New Drug Clearance for Live Biotherapeutic Product to Treat Atopic Dermatitis concertobio.com ↗
The IND clearance for ENS-002 is also an important moment for the field of microbial therapeutics. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-28 | Concerto Biosciences | Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis concertobio.com ↗ |
| 2024-11-19 | Concerto Biosciences | Concerto Biosciences Announces First Participant Dosed with Live Biotherapeutic ENS-002 in Phase 1 Trial for Atopic Dermatitis concertobio.com ↗ |
| 2024-06-26 | Concerto Biosciences | Concerto Biosciences Receives FDA Investigational New Drug Clearance for Live Biotherapeutic Product to Treat Atopic Dermatitis concertobio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENS-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06469385 ↗ |
| Modality | Other / unclassified | “live biotherapeutic product (LBP)” NCT06469385 ↗ |
| Route | Topical | “to be applied topically” NCT06469385 ↗ |